The UK’s Path To Sustainable Biosimilars Is Paved With Challenges
Experts came together at the UK’s Westminster Health Forum to discuss the importance of healthy competition among biosimilar developers, pressing issues concerning sustainability and other challenges faced by biosimilars.
You may also be interested in...
With a tender and reference prices for adalimumab now in place, NHS England has raised its forecast for annual savings through biosimilar competition to half a billion pounds.
Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.
Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.